Good that we're advancing on multiple fronts in other large geographic markets. The key ADXS/ADRO differentiator will be proven efficacy results of Lm-LLO vs the LADD+ cocktail which could also render any previous patent actions in the US by ADRO as a, so what? It's reasonable to assume product approvals in Europe, Canada or perhaps even Asia may come sooner than a breakthrough approval in the US due to the reality of more stringent FDA regulatory guidelines currently in place. We have multiple shots on goal in a number of big market locations.
News 
Market Data 
Discover 
AI
